Lixte Biotechnology (NASDAQ:LIXT) Announces Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) announced its earnings results on Thursday. The company reported ($0.18) EPS for the quarter, FiscalAI reports.

Lixte Biotechnology Trading Up 2.4%

Shares of LIXT traded up $0.12 during trading hours on Friday, reaching $5.16. The company had a trading volume of 149,390 shares, compared to its average volume of 60,573. Lixte Biotechnology has a 12-month low of $0.64 and a 12-month high of $6.26. The firm has a 50 day simple moving average of $3.43 and a 200-day simple moving average of $3.64. The company has a market capitalization of $59.96 million, a price-to-earnings ratio of -4.57 and a beta of 1.04.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Axxcess Wealth Management LLC purchased a new stake in shares of Lixte Biotechnology during the 4th quarter worth approximately $54,000. XTX Topco Ltd acquired a new position in shares of Lixte Biotechnology during the 4th quarter worth $57,000. Geode Capital Management LLC grew its stake in Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after acquiring an additional 10,722 shares during the last quarter. DRW Securities LLC raised its position in Lixte Biotechnology by 11.6% during the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock worth $213,000 after acquiring an additional 5,645 shares during the last quarter. Finally, Federation des caisses Desjardins du Quebec lifted its holdings in shares of Lixte Biotechnology by 83.6% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after purchasing an additional 42,530 shares in the last quarter. 5.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lixte Biotechnology in a report on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.